



**World Health
Organization**

**Department of Immunization,
Vaccines and Biologicals (IVB)**

SAGE

meeting

SLIDE DECKS

**Strategic Advisory Group of Experts
on Immunization
20-23 March 2023**





**Hybrid meeting, WHO
Geneva, Switzerland**

Note: To work properly this pdf needs to be downloaded on your computer (PC/Mac) and opened in Acrobat reader. It is does not function correctly in an internet browser window or on handheld devices.






**Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization
20-23 March 2023
Hybrid Meeting.
WHO HQ
Agenda**

Day 1: Monday, 20 March 2023 (time is Central European Time)



Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
9:30	Closed SAGE meeting	Preparation of the sessions of the day.	1h
10:30	Break	Break	15 min.
10:45	Opening and welcome – introduction of participants K. O'BRIEN. Immunization, Vaccines and Biologicals (IVB) Director. WHO. H. NOHYNEK. SAGE chair. J. HOMBACH. SAGE Executive Secretariat. WHO.		20 min.
11:05	Global reports – Session 1	FOR INFORMATION	1h 20 min.
	 Report from the Director of IVB. K. O'BRIEN. WHO. 30 min.		
	 Update from Gavi. S. BERKLEY. GAVI. 25 min. Discussion. 25 min.		
12:25	Break	Break	50 min.
13:15	Regional reports with deep dive on measles – Session 2	FOR DISCUSSION	2h
	Reports from the WHO Regions.  AFRO and EMRO. 10 min. each + 15 min. Q&A EURO and PAHO. 10 min. each + 15 min. Q&A WPRO and SEARO. 10 min. each + 15 min. Q&A Discussion. 30 min.		
15:15	Break	Break	15 min.
15:30	Partnering with regions and countries to identify priority pathogens for new vaccines – Session 3	FOR INFORMATION	45 min.
	 Introduction. K. POKU ASANTE. IA2030 SP7 WG co chair. 4 min. Presentation. B GIERSING. WHO. 20 min. Reflexions from one Regional Technical Advisory Group Chair (RITAG) chair. H. REES. AFR RITAG chair. Z. MEMISH. EMR RITAG chair. 6 min. Discussion. 15 min.	This session will provide an overview of WHO's approach and methodology to identify priority pathogens for new vaccine development at the regional and global levels. SAGE members may provide feedback on: - the progress of this work to date, and - proposals to finalise an initial list of priority pathogens for monitoring and evaluation through SP7.	
16:15	End of day		

Day 2: Tuesday 21 March 2023

Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
9:30	Closed SAGE meeting	Development of recommendations of day 1. Preparation of the sessions of the day. Other important discussion items.	1h 30 min.
11:00	Break	Break	15 min.
11:15	Covid-19 – Session 4 <i>Roadmap for COVID-19 vaccination in the era of Omicron</i> Introduction. S. KOCHHAR. SAGE member, SAGE C19 WG chair. A. WILDER SMITH. WHO. 10 min. Rationale for and distinctive characteristics of priority-use groups. R. FADEN. Johns Hopkins University. 10 min. Discussion. 10 min.  Evidence review: Protection over time from hybrid immunity, infection-induced immunity, vaccine-induced immunity in older persons: N. BOBROWITZ. University of Calgary. 10 min. Policy recommendation. 5 min. Discussion. 10 min. Evidence review: Number needed to vaccinate (NNV) data and waning vaccine effectiveness against severe disease outcomes, NNV for this age group, benefit versus risk. D. FEIKIN. WHO. 10 min. Policy recommendation. 5 min. Discussion. 10 min. Evidence review: epidemiology, clinical severity, long COVID, vaccine performance in young children, NNV. S. OMER. SAGE member. 15 min. Policy recommendation. 5 min. Discussion. 10 min.	FOR RECOMMENDATION To review strategies and policies to optimize the global impact of COVID-19 vaccines in the era of Omicron. Rationale for an update of the Roadmap. Policy question 1: What is the optimal timing for additional booster doses in older persons? Policy question 2: Do healthy younger adults (aged 18-59 years or 18-49 years) need additional boosters? Policy question 3: Do healthy children and adolescents (aged 6 months to 17 years) still need primary series in the era of Omicron and high population immunity?	1h 30 min.
12:45	Break	Break	1h
13:45	Covid-19 – Session 4 (continued) <i>Roadmap for COVID-19 vaccination in the era of Omicron</i> Evidence review: incidence and deaths in health workers in the era of Omicron and high population immunity. P. SMITH. LSHTM. 10 min. Policy recommendation. 5 min. Discussion. 10 min.  Evidence and rationale for protecting the pregnant woman, foetus and infant up to age 6 months: S. GOTTLIEB. WHO. 10 min. Policy recommendation. 5 min. Discussion. 10 min. Presentation of final Roadmap table and Recommendations. S. KOCHHAR. SAGE member, SAGE C19 WG chair. 10 min. Discussion. 10 min.	FOR RECOMMENDATION Policy question 4: Do health workers need additional booster doses? Policy question 5: Do pregnant persons need additional booster doses?	1h 30 min.
15:15	Break	Break	15 min.
15:30	Status of new TB vaccine candidates intended for adults and adolescents: preparing the pathway for use – Session 5	FOR DISCUSSION The purpose of this session is to:	1h 30 min.

 <p>Opening comments: S. KOCHHAR. SAGE member. 5 min.</p> <p>Current TB disease burden. M. ZIGNOL. WHO. 5 min.</p> <p>Current pipeline of candidates for adults and adolescents, high level description of WHO tools to prepare the pathway to policy and access. B. GIERSING. WHO. 10 min.</p> <p>Full Value of Vaccines for TB vaccines meeting the WHO PPC. R. WHITE. LSHTM. N. MENZIES. Harvard University. 20 min.</p> <p>M72/AS01E-4 product development overview. A. SCHMIDT. Gates Medical Research Institute. 20 min.</p> <p>Discussion. 30 min.</p>	<p>Provide a brief status overview of the TB vaccine candidates intended for use in adults and adolescents;</p> <ul style="list-style-type: none"> - Describe the tools that WHO is developing to prepare the pathway for new TB vaccine use in high burden countries, including the development of a Full Value of Vaccines Assessment (FVVA); - Present an overview of the M72/AS01E product development plans, including the efficacy study design and licensure strategy. - Seek feedback from SAGE on the proposed clinical development design and regulatory strategy for M72/AS01E, and more broadly the preparatory activities for new TB vaccines for adults and adolescents.
17:00 End of the day	

Day 3: Wednesday 22 March 2023

Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
9:30	Closed SAGE meeting	Development of recommendations of day 2. Preparation of the sessions of the day. Other important discussion items.	1h 30 min.
11:00	Break	Break	15 min.
11:15	Polio – Session 6	FOR RECOMMENDATION	2h 15 min.
	 <p>Session overview by S. MADHI, SAGE Member, SAGE Polio WG chair. 5 minutes</p> <p>Update from the Global Polio Eradication Initiative. A. O'LEARY. WHO. 20 min.</p> <p>Questions: 30 min.</p> <p>Strategies for areas of persistent poliovirus transmission. O. MACH. WHO. 15 min</p> <p>Questions: 10 min.</p> <p>Summary of data from study on use of nOPV2 in a short interval. A. BANDYOPADHYAY. BMGF. 10 min.</p> <p>Questions: 10 min.</p> <p>Report from SAGE Polio Working Group including update on novel OPVs. S. MADHI. SAGE member, SAGE Polio WG chair. 15 min.</p> <p>Discussion: 20 min.</p>	<p>SAGE will be informed on the current status of the polio eradication programme and of the implementation of the new polio eradication strategy. SAGE will be updated on the use and clinical development of novel oral poliovirus vaccines (OPVs).</p> <p>SAGE will be asked to review and consider for endorsement:</p> <ul style="list-style-type: none"> - Recommendation to restrict use of Sabin type 2 oral vaccine. - Recommendation on immunization strategies for areas with persistent poliovirus transmission and role of IPV in these areas. - Recommendation on use of nOPV2 in shorter than a four-week interval. 	
13:30	Break	Break	1h
14:30	Malaria – Session 7	FOR INFORMATION	2h
	 <p>Update on the Malaria Vaccine Implementation Programme (MVIP) and progress. M. HAMEL/ E. FURRER. WHO. 20 min.</p> <ul style="list-style-type: none"> - Brief update on the MVIP. - Supply situation & Framework for allocation of limited supply. - Malaria vaccine applications to Gavi & next steps for scale-up. <p>Q&A. 15 min.</p>	To update SAGE on the Malaria Vaccine Implementation Programme (MVIP) and the RTS,S/AS01 malaria vaccine roll-out.	

Implementation guidance on seasonal vaccination strategy in areas of highly seasonal malaria transmission or perennial malaria with seasonal peaks. M. HAMEL. WHO/ P. SMITH. LSTHM. 15 min.

- Background on seasonal malaria vaccination.
- Presentation of WG recommendations.

Q&A. 15 min.

Update on the malaria vaccine candidate: R21/MatrixM. M. HAMEL/ L. WU. WHO. 10 min.

- Status of evidence review and recommendation process
- Key conclusions of SAGE/MPAG WG initial data review meeting.
- Future meetings and next steps.

Q&A. 15 min.

Discussion. 30 min.

FOR DISCUSSION

To ask SAGE advise on implementation guidance—based on the 2021 malaria vaccine position paper—for seasonal vaccination schedules in areas with highly seasonal malaria transmission or perennial malaria areas with seasonal peaks.

FOR INFORMATION

To update SAGE on the evidence review and recommendation processes for malaria vaccine candidate R21/MatrixM.

16:30 Closing

5 min.

A. BANERJEE. ADG/UHL i.a. WHO. 5 min.

16:35 End of the plenary meeting

**Day 4: Thursday 23 March 2023
CLOSED MEETING ONLY**